The left navigation bar requires Javascript to be enabled. Please enable Javascript on your browser or
use the Site Map
to navigate.
Contact Newsroom
Podcast
RSS
These product press releases are intended for use in the United States only. Countries outside of the U.S. may have different regulatory requirements and review practices that may require referencing different information.
28 Apr 2008
Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant)
25 Apr 2008
Schering-Plough/Merck Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
24 Apr 2008
Two Merck Medicines Recommended for Approval in the European Union
17 Apr 2008
Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV™
01 Apr 2008
Merck's Investigational Rolofylline Associated with Improved Dyspnea and Preserved Renal Function in Acute Heart Failure Patients in a Phase III Pilot Study
31 Mar 2008
Update on ACHIEVE: A Study of Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™)
31 Mar 2008
Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss
31 Mar 2008
Patients Treated with Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™) Reported Significantly Less Flushing Than Patients Treated with Niaspan™ in Phase III Study
17 Mar 2008
Merck Scientists Apply Innovative Research Method to Identify Changes in Gene Networks Linked to Obesity
Studies Published in
Nature
17 Mar 2008
Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
13 Nov 2007
STEP Study Volunteers to be Informed Whether They Received Vaccine or Placebo
07 Nov 2007
Data from STEP Study Presented at Open Scientific Session Confirm Merck's Investigational HIV Vaccine was not Effective
06 Nov 2007
GTx, Inc. and Merck & Co., Inc. Enter Global Strategic Collaboration for the Development of SARMs, a Novel Investigational Class of Drugs to Treat Muscle Loss and other Musculoskeletal Conditions
05 Nov 2007
Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™) Coadministered with Simvastatin Had Significant Additive Effects on LDL-C, HDL-C and Triglycerides in Phase III Study
01 Nov 2007
Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV™, an Investigational Hepatitis B Vaccine Currently in Phase 3
top
Printer Friendly Page